Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.62 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.62 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.62 |
| ▸ | CDK2 | P24941 | 1/20 | 0.62 |
| ▸ | PPARG | P37231 | 4/20 | 0.61 |
| ▸ | PPARD | Q03181 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22349529 | 0.87 | CDK1 (0.76) | CDK1ADORA3ADORA2AADORA1CCNE2 | |
| SCHEMBL6820865 | 0.87 | PPARG (0.65) | ADORA3ADORA2AADORA1PPARGPPARD | |
| SCHEMBL3059627 | 0.86 | CDK1 (0.74) | CDK1ADORA3ADORA2AADORA1CCNE2 | |
| SCHEMBL28771314 | 0.86 | CDK1 (0.74) | CDK1ADORA3ADORA2AADORA1CCNE2 | |
| SCHEMBL7099155 | 0.86 | CDK1 (0.74) | CDK1ADORA3ADORA2AADORA1CCNE2 | |
| SCHEMBL6820864 | 0.86 | CDK1 (0.76) | CDK1ADORA3ADORA2AADORA1PPARG | |
| SCHEMBL8010398 | 0.86 | CDK1 (1.00) | CDK1CCNE2CCNE1CDK2 | |
| SCHEMBL450530 | 0.85 | CDK1 (0.57) | CDK1ADORA3ADORA2ACCNE2CCNE1 | |
| SCHEMBL29501930 | 0.85 | CDK1 (0.57) | CDK1ADORA3ADORA2ACCNE2CCNE1 | |
| SCHEMBL449338 | 0.84 | CDK1 (0.53) | CDK1CCNE2CCNE1CDK2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825102-B2 | Treatment of dry eye conditions | CAN-FITE BIOPHARMA LTD. (IL) | 2010-11-02 | — | — | US | claimed |
| EP-1778239-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS INCLUDING SJOGREN'S SYNDROME | Can-Fite Biopharma Ltd. (IL) | 2007-05-02 | — | — | EP | claimed |
| US-7064112-B1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-06-20 | — | — | US | claimed |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-04-20 | — | — | US | claimed |
| WO-2006011130-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS INCLUDING SJOGREN’S SYNDROME | CAN-FITE BIOPHARMA LTD. (IL) | 2006-02-02 | — | — | WO | claimed |
| US-20260115218-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | CAN-FITE BIOPHARMA LTD. (IL) | 2026-04-30 | — | — | US | disclosed |
| US-12213990-B2 | A3 adenosine receptor ligand for use for achieving a fat loss effect | CAN-FITE BIOPHARMA LTD. (IL) | 2025-02-04 | — | — | US | disclosed |
| EP-3530273-B1 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN THE TREATMENT OF A SEXUAL DYSFUNCTION | CAN FITE BIOPHARMA LTD (IL) | 2024-08-14 | — | — | EP | disclosed |
| US-20230201240-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | CAN-FITE BIOPHARMA LTD. (IL) | 2023-06-29 | — | — | US | disclosed |
| US-11291681-B2 | Method for treating fibrotic liver tissue using Cl-IB-MECA | CAN-FITE BIOPHARMA LTD. (IL) | 2022-04-05 | — | — | US | disclosed |
| US-20220079968-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | CAN-FITE BIOPHARMA LTD. (IL) | 2022-03-17 | — | — | US | disclosed |
| EP-3906034-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | Can-Fite Biopharma Ltd. (IL) | 2021-11-10 | — | — | EP | disclosed |
| EP-1959939-A1 | USE OF A3 ADENOSINE RECEPTOR AGONIST IN OSTEOARTHRITIS TREATMENT | Can-Fite Biopharma Ltd. (IL) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007086044-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS | CAN-FITE BIOPHARMA LTD. (IL) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007063538-A1 | USE OF A3 ADENOSINE RECEPTOR AGONIST IN OSTEOARTHRITIS TREATMENT | CAN-FITE BIOPHARMA LTD. (IL) | 2007-06-07 | — | — | WO | disclosed |
| US-20070099865-A1 | Treatment of dry eye conditions | CAN-FITE BIOPHARMA LTD. (IL) | 2007-05-03 | — | — | US | disclosed |
| EP-1778239-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS INCLUDING SJOGREN'S SYNDROME | Can-Fite Biopharma Ltd. (IL) | 2007-05-02 | — | — | EP | disclosed |
| US-7064112-B1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-06-20 | — | — | US | disclosed |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | CAN-FITE BIOPHARMA LTD. (IL) | 2006-04-20 | — | — | US | disclosed |
| WO-2006011130-A1 | ADENOSINE A3 RECEPTOR AGONISTS FOR THE TREATMENT OF DRY EYE DISORDERS INCLUDING SJOGREN’S SYNDROME | CAN-FITE BIOPHARMA LTD. (IL) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11291681-B2 | Method for treating fibrotic liver tissue using Cl-IB-MECA | GPR119, FABP1, INSR | CDK1 4630/4885ADORA3 12/4885ADORA2A 4/4885 |
| US-20070099865-A1 | Treatment of dry eye conditions | ADORA3, ADORA2A, ADORA2B | CDK1 4171/4885ADORA3 1/4885ADORA2A 2/4885 |
| US-20220079968-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | ADORA2A, ADORA3, FABP4 | CDK1 3046/4885ADORA3 2/4885ADORA2A 1/4885 |
| US-20230201240-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | ADORA3, ADORA2A, ADORA1 | CDK1 1237/4885ADORA3 1/4885ADORA2A 2/4885 |
| US-20260115218-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | ADORA2B, ADORA3, ADORA2A | CDK1 1481/4885ADORA3 2/4885ADORA2A 3/4885 |
| US-12213990-B2 | A3 adenosine receptor ligand for use for achieving a fat loss effect | ADORA3, ADORA2A, FABP4 | CDK1 3037/4885ADORA3 1/4885ADORA2A 2/4885 |
| US-20060084626-A1 | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist | ADORA2A, ADORA3, ADORA1 | CDK1 1240/4885ADORA3 2/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.